[The viewpoint of the medical oncologist].
Benasso
Marco
M
Istituto Nazionale per la Ricerca sul Cancro, Genova.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D000077143:Docetaxel; D023381:Endpoint Determination / Q000379:methods / Q000639:trends; D019317:Evidence-Based Medicine; D006801:Humans; D008495:Medical Oncology; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D000077143:Docetaxel